Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Regeneron’s bid to join the market for BCMA-targeted bispecific antibodies for multiple myeloma is nearing a conclusion, with the FDA starting a priority review of its linvoseltamab drug candidate.

Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in the ...

Regeneron Pharmaceuticals Inc (REGN) reports robust financial performance with a 10% revenue increase and unveils new ...

Regulatory setbacks, including the FDA’s complete response letter for linvoseltamab, further contributed to investor concerns. Analysts' consensus rating on Regeneron Pharmaceuticals stock is ...

Regeneron’s pipeline is a key differentiator, particularly in oncology, with significant progress in submissions for linvoseltamab and odronextamab, and positive data for Libtayo in adjuvant CSCC.

Regeneron recently announced that the primary ... The FDA issued a CRL for the BLA for linvoseltamab, a bispecific antibody targeting BCMA and CD3, in R/R multiple myeloma that has progressed ...

Linvoseltamab (BCMAxCD3 ... Factor XI for anticoagulation: Regeneron’s two-pronged approach to anticoagulation is being evaluated for its potential to control thombosis while minimizing bleeding ...

Regeneron collaborates with Truveta and leading American ... with a potential BLA submission to follow. Linvoseltamab (BCMAxCD3) for multiple myeloma: Linvoseltamab has potential to be the ...